BIOMAT Database Logo BIOMAT Database Logo

OKT3 therapy for hepatic allograft rejection. Differential response in adults and children. 1991

E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
Department of Surgery, University of Chicago Pritzker School of Medicine, Illinois.

The clinical courses following OKT3 therapy for hepatic allograft rejection (HAR) in adults and children have not been individually defined. We have reviewed our experience with OKT3 therapy for HAR in adults and children to compare: (1) the initial response to OKT3 therapy, (2) the clinical course following OKT3 therapy, and (3) the antimurine antibody response and immunologic monitoring results. Children required OKT3 therapy more frequently than adults: fourteen courses of OKT3 therapy were required in 130 orthotopic liver transplants (OLT) in 108 adult patients, whereas nineteen courses of OKT3 therapy were required in 94 OLT in 78 children (P less than 0.02). Repeat OKT3 therapy was not required in adults--however, four of nineteen courses of OKT3 therapy in children were repeat OKT3 therapy for rejection. No differences existed between adult and pediatric treatment groups with respect to number of prior OLT procedures, previous graft loss to rejection, percentage of ABO-incompatible grafts, frequency of positive donor-recipient lymphocyte crossmatches, or time to first rejection. The initial response to OKT3 therapy (rapid reversal, delayed reversal, and failure) was remarkably similar in adults and children. However, nine of 13 (70%) children with clear evidence of response to OKT3 treatment experienced breakthrough rejection or early recurrent rejection, whereas none of 12 adults suffered breakthrough rejection or early recurrent rejection (P less than 0.01). Early recurrent rejection did not correlate with delayed reversal of rejection, early return of CD3+ cells by peripheral blood monitoring, or development of anti-OKT3 antibodies. All 4 courses of OKT3 retreatment in children were successful in reversing rejection, and breakthrough rejection and early recurrent rejection did not occur. Overall graft and patient survival in pediatric patients requiring OKT3 therapy (67% and 73%) was not different from that in adults (71% and 79%). Results obtained in one patient provide the first evidence that successful OKT3 retreatment of HAR can be achieved in the presence of preexisting idiotypic anti-OKT3 antibody. In conclusion, OKT3 therapy for HAR was required more frequently in children than in adults. The clinical outcome following OKT3 therapy for HAR also differs markedly, with early recurrent rejection and breakthrough rejection occurring more frequently in children.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000888 Antibodies, Anti-Idiotypic Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies. Anti-Antibodies,Anti-Idiotype Antibodies,Antibodies, Internal Image,Antigamma Globulin Antibodies,Antiglobulins,Anti Antibodies,Anti-gamma Globulin Antibodies,Anti Idiotype Antibodies,Anti gamma Globulin Antibodies,Anti-Idiotypic Antibodies,Antibodies, Anti,Antibodies, Anti Idiotypic,Antibodies, Anti-Idiotype,Antibodies, Anti-gamma Globulin,Antibodies, Antigamma Globulin,Globulin Antibodies, Anti-gamma,Globulin Antibodies, Antigamma,Image Antibodies, Internal,Internal Image Antibodies
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
OKT3 for steroid-resistant renal allograft rejection: differential response in adults and children.
August 1994, Transplantation proceedings,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
Histologic response to OKT3 therapy for hepatic allograft rejection.
February 1987, Transplantation proceedings,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
OKT3 rescue therapy in pancreas-allograft rejection.
January 1989, Diabetes,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
OKT3 in the reversal of acute hepatic allograft rejection.
February 1987, Transplantation proceedings,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
Post-OKT3 induction therapy CD complex response predicts renal allograft rejection.
April 1997, Transplantation,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
Liver allograft rejection: analysis of OKT3 rescue therapy.
October 1992, Transplantation proceedings,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
Primary therapy with OKT3 for biopsy-proven acute renal allograft rejection.
June 1998, Transplantation proceedings,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection.
February 1987, Transplantation proceedings,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection.
January 1987, Transplantation,
E S Woodle, and J R Thistlethwaite, and J C Emond, and P F Whitington, and D D Black, and P P Aran, and A L Baker, and F P Stuart, and C E Broelsch
OKT3 treatment of cardiac allograft rejection.
January 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Copied contents to your clipboard!